Ultragenyx Pharmaceutical Inc (RARE) Stake Increased by Iguana Healthcare Management LLC

Iguana Healthcare Management LLC grew its holdings in Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) by 20.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 60,000 shares of the biopharmaceutical company’s stock after buying an additional 10,000 shares during the quarter. Ultragenyx Pharmaceutical comprises 2.0% of Iguana Healthcare Management LLC’s investment portfolio, making the stock its 16th biggest holding. Iguana Healthcare Management LLC owned 0.12% of Ultragenyx Pharmaceutical worth $3,059,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Profund Advisors LLC increased its stake in Ultragenyx Pharmaceutical by 5.6% in the 1st quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 889 shares in the last quarter. American Century Companies Inc. increased its stake in Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock valued at $1,872,000 after purchasing an additional 997 shares in the last quarter. Wells Fargo & Company MN increased its stake in Ultragenyx Pharmaceutical by 5.0% in the 1st quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock valued at $1,234,000 after purchasing an additional 1,149 shares in the last quarter. RMB Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 3.3% in the 1st quarter. RMB Capital Management LLC now owns 45,178 shares of the biopharmaceutical company’s stock valued at $2,304,000 after purchasing an additional 1,445 shares in the last quarter. Finally, Verity Asset Management Inc. increased its stake in Ultragenyx Pharmaceutical by 26.4% in the 1st quarter. Verity Asset Management Inc. now owns 7,245 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 1,512 shares in the last quarter. 96.11% of the stock is owned by institutional investors and hedge funds.

In related news, EVP Karah Herdman Parschauer sold 1,465 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $60.00, for a total value of $87,900.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Shalini Sharp sold 13,000 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, May 30th. The shares were sold at an average price of $70.17, for a total value of $912,210.00. Following the completion of the transaction, the chief financial officer now owns 70,174 shares in the company, valued at approximately $4,924,109.58. The disclosure for this sale can be found here. Insiders have sold 29,777 shares of company stock worth $2,174,466 in the last 90 days. Insiders own 8.40% of the company’s stock.



Several equities analysts recently weighed in on the company. BidaskClub downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, May 1st. ValuEngine raised Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. Cowen reissued a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 18th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $62.00 to $74.00 in a research report on Friday, May 11th. Finally, JMP Securities raised their price target on Ultragenyx Pharmaceutical from $70.00 to $74.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $70.06.

RARE stock opened at $82.72 on Friday. Ultragenyx Pharmaceutical Inc has a 52-week low of $41.67 and a 52-week high of $84.23.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Monday, May 7th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.81. The business had revenue of $10.68 million for the quarter, compared to analyst estimates of $56.58 million. During the same quarter last year, the business earned ($1.63) EPS. equities analysts predict that Ultragenyx Pharmaceutical Inc will post -5.32 earnings per share for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply